FrancophonIA/ELRC3.0 huggingface dataset:
English: Detailed information on this medicinal product is available on the website of the European Medicines Agency: http://www.ema.europa.eu
Danish: De kan finde yderligere oplysninger om OSSEOR på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu/.
English: Pack sizes
Danish: Pakningsstørrelser:
English: In the absence of bone safety data in patients with severe renal impairment treated with strontium ranelate, OSSEOR is not recommended in patients with a creatinine clearance below 30 ml/min (see section 5.2).
Danish: Da der ikke foreligger data for knoglerelateret sikkerhed hos strontiumranelatbehandlede patienter med alvorligt nedsat nyrefunktion, anbefales OSSEOR ikke til patienter med kreatininclearance < 30 ml/min (se pkt.
English: Measurement of strontium concentration in iliac crest bone biopsies from patients treated for up to 60 months with strontium ranelate 2 g/day indicate that bone strontium concentrations may reach a plateau after about 3 years of treatment.
Danish: I biopsier fra crista iliaca hos patienter, der havde fået 2 g strontiumranelat daglig i op til 60 måneder, indicerer målinger af strontiumkoncentration, at knoglekoncentrationerne stabiliseres efter ca. 3 års behandling.
English: Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis) have been reported (see section 2).
Danish: Potentielt livstruende hududslæt (Stevens-Johnsons syndrom, toksisk epidermal nekrolyse) er rapporteret (se punkt 2).
English: No evidence of clinical interactions or relevant increase of blood strontium levels with medicinal products expected to be commonly prescribed concomitantly with OSSEOR in the target population were found during clinical trials.
Danish: Der er i kliniske studier ikke påvist klinisk interaktion eller relevant stigning i plasmakoncentrationen af strontium med lægemidler, som normalt kan forventes at blive ordineret samtidig med OSSEOR til målgruppen.
English: Treatment of severe osteoporosis:
Danish: Behandling af svær osteoporose:
English: However, osteoporosis makes you more likely to have fractures (break bones), especially in your spine, hips and wrists.
Danish: Osteoporose øger sandsynligheden for knoglebrud eller frakturer, især i ryg, hofter og håndled.
English: Given the slow absorption, OSSEOR should be taken at bedtime, preferably at least two hours after eating (see sections 4.5 and 5.2).
Danish: På grund af den langsomme absorption bør OSSEOR tages ved sengetid og fortrinsvis mindst 2 timer efter et måltid (se pkt.
English: - If you take antacids (medicines to relieve heartburn) you should take them at least 2 hours after OSSEOR.
Danish: - Hvis De får syreneutraliserende medicin (mod halsbrand), skal De helst tage dem mindst 2 timer efter, at De tager OSSEOR.
English: New clinical vertebral fracture over 3 years
Danish: Nye kliniske vertebralfrakturer i løbet af 3 år
English: In phase III studies, the annual incidence of venous thromboembolism (VTE) observed over 5 years was approximately 0.7%, with a relative risk of 1.4 (95% CI = [1.0 ; 2.0]) in strontium ranelate treated patients as compared to placebo (see section 4.4).
Danish: I fase III-studier observeredes en årlig incidens af venøse tromboemboliske komplikationer (VTE) i løbet af 5 år på ca. 0,7 % med en relativ risiko på 1,4 (95 % CI = [1,0 - 2,0]) hos patienter behandlet med strontiumranelat sammenlignet med placebo (se pkt.
English: EU/1/04/287/005/ 84 sachets (3 packs of 28) EU/1/04/287/006 100 sachets
Danish: EU/1/04/287/005 84 breve (3 pakker med 28 i hver) EU/1/04/287/006 100 breve
English: In postmenopausal women, strontium ranelate reduces the risk of fracture at the spine and at the hip.
Danish: Hos kvinder, der er holdt op med at menstruere, reducerer strontiumranelat risikoen for brud på rygsøjle og hofte.
English: Good tolerance was shown in a clinical study investigating the repeated administration of 4 g strontium ranelate per day over 25 days in healthy postmenopausal women.
Danish: I et klinisk studie, der undersøgte gentagne doser på 4 g strontiumranelat daglig i 25 dage hos raske postmenopausale kvinder, viste lægemidlet sig at være veltolereret.
English: You can take OSSEOR again when you have finished taking these antibiotics.
Danish: Når behandlingen med antibiotika er afsluttet, kan De atter begynde at tage OSSEOR.
English: If you are unsure about this ask your doctor or pharmacist.
Danish: Er De i tvivl, så spørg lægen eller på apoteket.
English: If symptoms or signs of SJS or TEN (e.g. progressive skin rash often with blisters or mucosal lesions) or DRESS (e.g. rash, fever, eosinophilia and systemic involvement (e.g. adenopathy, hepatitis, interstitial nephropathy, interstitial lung disease) are present, OSSEOR treatment should be discontinued immediately.
Danish: Hvis der er symptomer eller tegn på SJS eller TEN (fx progressivt udslæt, ofte med blister, eller slimhindelæsioner) eller på DRESS (fx udslæt, feber, eosinofili og systemisk påvirkning (fx adenopati, hepatitis, interstitiel nefropati, interstitiel lungesygdom)), bør OSSEOR øjeblikkeligt seponeres.
English: As divalent cations can form complexes with oral tetracycline and quinolone antibiotics at the gastrointestinal level and thereby reduce their absorption, simultaneous administration of strontium ranelate with these medicinal products is not recommended.
Danish: Divalente kationer kan danne komplekser med peroralt tetracyclin og quinolon i det gastrointestinale system, hvorved absorptionen af disse antibiotika reduceres.
English: Posology The recommended dose is one 2 g sachet once daily by oral administration.
Danish: Dosering Anbefalet dosis er 1 brev med 2 g én gang daglig per os.
English: There is no pharmacokinetic data in patients with severe renal impairment (creatinine clearance below 30 ml/min).
Danish: Der foreligger ingen farmakokinetiske data fra patienter med alvorlig nyrefunktionsnedsættelse (kreatininclearance < 30 ml/min).
English: Each sachet contains 2 g of strontium ranelate.
Danish: Et brev indeholder 2 g strontiumranelat.
English: In Asian countries reported as rare d In pooled placebo-controlled studies of post-menopausal osteoporotic patients, strontium ranelate treated patients (N=3803, 11270 patient years of treatment) compared to placebo (N=3769, 11250 patient years of treatment)
Danish: I poolede, placebokontrollerede studier af postmenopausale osteoporotiske patienter, strontiumranelatbehandlede patienter (n=3803, 11.270 patient-år med behandling) sammenlignet med placebo (n=3769, 11.250 patient-år med behandling)
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each sachet contains 2 g strontium ranelate.
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Et brev indeholder 2 g strontiumranelat.
English: In pooled randomised placebo-controlled studies of post-menopausal osteoporotic patients, a significant increase in myocardial infarction has been observed in OSSEOR treated patients compared to placebo (see section 4.8).
Danish: I poolede, randomiserede, placebokontrollerede studier med postmenopausale, osteoporotiske patienter er der observeret en betydeligt højere frekvens af myokardieinfarkt hos OSSEORbehandlede patienter sammenlignet med placebo (se pkt.
English: 28 sachets
Danish: 28 breve.
English: Τηλ: +357 22741741
Danish: Χ.Α.Παπαέλληνας & Σία Λτδ Τηλ: +357 22741741
English: Vomiting, abdominal pain, reflux, indigestion, constipation, flatulence, dry mouth, pins and needles, dizziness, vertigo, difficulty in sleeping, inflammation of the liver (hepatitis), oral irritation (such as mouth ulcers and gum inflammation), bone, muscle and/or joint pain, muscle cramps, hair loss, reduction in production of blood cells in the bone marrow, itching, hives, blistering, angioedema
Danish: Opkastning, mavesmerter, sure opstød, fordøjelsesbesvær, forstoppelse, luftafgang fra tarmen, mundtørhed, prikken og stikken, svimmelhed, vertigo (følelse af at dreje rundt), søvnbesvær, leverbetændelse (hepatitis), irritation i munden (såsom mundsår og tandkødsbetændelse), smerter i knogler, muskler og/eller led, muskelkramper, hårtab, nedsat produktion af blodlegemer i knoglemarven, kløe, nældefeber, blærer, angioødem (såsom hævelser i ansigt, tunge eller hals, besvær med at trække vejret eller synke), hævelser i arme og ben, utilpashed, forvirring, bronkial hyperreaktivitet (symptomerne omfatter hiven efter vejret, åndenød og hoste).
English: o If symptoms or signs of Stevens-Johnson Syndrome (SJS), Toxic Epidermal Necrolysis (TEN) or Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) (e.g. rash, fever, eosinophilia and systemic involvement, e.g. adenopathy, hepatitis, interstitial nephropathy, interstitial lung disease) are present, OSSEOR treatment should be discontinued immediately.
Danish: o Hvis der opstår symptomer eller tegn på Stevens-Johnsons syndrom (SJS), toksisk epidermal nekrolyse (TEN) eller medikamentelt udslæt med eosinofili og systemiske symptomer (DRESS) (fx udslæt, feber, eosinofili og systemisk påvirkning, fx adenopati, hepatitis, interstitiel neuropati, interstitiel lungesygdom), bør OSSEORbehandlingen øjeblikkelig afbrydes.
English: Current or previous venous thromboembolic events (VTE), including deep vein thrombosis and pulmonary embolism.
Danish: Anamnese med nuværende eller tidligere venøse tromboemboliske komplikationer (VTE) inklusive dyb venøs trombose og lungeemboli.
English: o Current or previous venous thromboembolic events (VTE), including deep vein thrombosis and pulmonary embolism.
Danish: o Anamnese med nuværende eller tidligere venøse tromboemboliske komplikationer (VTE) inklusive dyb venøs trombose og lungeemboli.
English: Potentially life-threatening skin rashes (Stevens-Johnson syndrome, toxic epidermal necrolysis and severe hypersensitivity reactions (DRESS)) have been reported with the use of OSSEOR.
Danish: Der er rapporteret potentielt livstruende hududslæt (Stevens-Johnsons syndrom, toksisk epidermal nekrolyse og svære overfølsomhedsreaktioner (DRESS)) ved anvendelse af OSSEOR.
English: Uncommon: Seizures.
Danish: Ikke almindelig: Krampeanfald.
English: Temporary or permanent immobilisation due to e.g. post-surgical recovery or prolonged bed rest.
Danish: Midlertidig eller permanent immobilisation fx under restitution efter kirurgi eller ved længerevarende sengeleje.
English: OSSEOR should be discontinued as soon as possible in the event of an illness or a condition leading to immobilisation (see section 4.3) and adequate preventive measures taken.
Danish: 4.3), bør OSSEOR seponeres snarest muligt, og der bør træffes passende forebyggende foranstaltninger.
English: No dose adjustment is required in patients with mild-to-moderate renal impairment (30-70 ml/min creatinine clearance) (see section 5.2).
Danish: Dosisjustering er ikke nødvendig hos patienter med let til moderat nyrefunktionsnedsættelse (kreatininclearance 30-70 ml/min) (se pkt.
English: Blood clots.
Danish: Blodpropper.
English: Life-threatening cutaneous reactions (Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and drug rash with eosinophilia and systemic symptoms (DRESS)) have been reported with the use of OSSEOR.
Danish: Livstruende hudreaktioner som Stevens-Johnsons syndrom (SJS), toksisk epidermal nekrolyse (TEN) og DRESS-syndromet (medikamentelt udslæt med eosinofili og systemiske symptomer) er rapporteret i forbindelse med OSSEOR.
English: What OSSEOR looks like and contents of the pack OSSEOR is available in sachets containing yellow granules for oral suspension.OSSEOR is supplied in boxes of 7, 14, 28, 56, 84 or 100 sachets.
Danish: OSSEOR udleveres i æsker med 7, 14, 28, 56, 84 eller 100 breve.
English: Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Danish: Brug af anden medicin sammen med OSSEOR Fortæl altid lægen eller apotekspersonalet, hvis De bruger anden medicin eller har gjort det for nylig.
English: Hip fracture over 3 years
Danish: Hoftefrakturer i løbet af 3 år
English: New vertebral fracture over 3 years
Danish: Nye vertebralfrakturer i løbet af 3 år
English: Talk to your doctor or pharmacist before taking OSSEOR: - if you are at risk of heart disease, this includes high blood pressure, high cholesterol, diabetes,
Danish: Kontakt lægen eller apotekspersonalet, før De tager OSSEOR: - hvis De har risiko for hjertesygdom.
English: When a VTE occurs, OSSEOR should be stopped.
Danish: I tilfælde af en venøs tromboembolisk komplikation bør OSSEOR seponeres.
English: 14 sachets
Danish: 14 breve.
English: If you have osteoporosis, your body breaks down more bone than it forms so that gradually bone loss occurs and your bones become thinner and fragile.
Danish: Når man har osteoporose eller knogleskørhed, nedbryder kroppen mere knoglevæv, end den danner.
English: 7 sachets
Danish: 7 breve.
English: If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis or DRESS with the use of OSSEOR, you must not be re-started on OSSEOR at any time If you develop a rash or these skin symptoms, stop taking OSSEOR, seek urgent advice from a doctor and tell him that you are taking this medicine.
Danish: Hvis De udvikler hududslæt eller de nævnte hudsymptomer, skal De stoppe med at tage OSSEOR og straks søge læge.
English: EXP
Danish: Eksem
English: België/Belgique/Belgien S.A. Servier Benelux N.V. Tel: +32 (0)2 529 43 11
Danish: België/Belgique/Belgien S.A. Servier Benelux N.V.
English: Puh/Tel: +358 (0)9 279 80 80
Danish: Suomi/Finland Servier Finland Oy Puh/Tel: +358 (0)9 279 80 80
English: Pregnancy and breast-feeding:
Danish: Graviditet og amning
English: MARKETING AUTHORISATION NUMBER(S) EU/1/04/287/004 56 sachets
Danish: MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/04/287/004 56 breve
English: OSSEOR is for oral use.
Danish: OSSEOR er beregnet til indtagelse gennem munden.
English: DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 21/09/2004
Danish: DATO FOR FØRSTE MARKEDSFØRINGSTILLADELSE/FORNYELSE AF TILLADELSEN
English: Percentage of Patients Experiencing the adverse reaction Treatment Strontium ranelate (n=3352)
Danish: Strontiumranelat (n=3.352)
English: Strontium ranelate is not recommended for patients with severe renal impairment (creatinine clearance below 30 ml/min) (see sections 4.4 and 5.2).
Danish: Strontiumranelat bør ikke anvendes til patienter med alvorligt nedsat nyrefunktion (kreatininclearance < 30 ml/min) (se pkt.
English: What OSSEOR is and what it is used for What you need to know before you take OSSEOR How to take OSSEOR
Danish: Det skal De vide, før De begynder at tage OSSEOR Sådan skal De tage OSSEOR Bivirkninger
English: Continuation of treatment with OSSEOR in patients developing severe renal impairment should be considered on an individual basis.
Danish: Hos patienter, der udvikler alvorligt nedsat nyrefunktion, bør det vurderes individuelt, om behandlingen med OSSEOR kan fortsættes.
English: NAME OF THE MEDICINAL PRODUCT OSSEOR 2 g granules for oral suspension Strontium ranelate
Danish: LÆGEMIDLETS NAVN OSSEOR 2 g granulat til oral suspension.
English: Venous thromboembolism
Danish: Venøs tromboembolisk sygdom
English: o Temporary or permanent immobilisation due to e.g. post-surgical recovery or prolonged bed rest. o Hypersensitivity to the active substance (strontium ranelate) or any of the excipients.
Danish: o Overfølsomhed over for det aktive stof (strontiumranelat) eller over for et eller flere af hjælpestofferne.
English: MARKETING AUTHORISATION NUMBER(S) EU/1/04/287/002
Danish: MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/04/287/002
English: MARKETING AUTHORISATION NUMBER(S) EU/1/04/287/003
Danish: MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/04/287/003
English: MARKETING AUTHORISATION NUMBER(S) EU/1/04/287/001
Danish: MARKEDSFØRINGSTILLADELSESNUMMER (-NUMRE) EU/1/04/287/001
English: Adverse Reaction
Danish: Hudreaktioner
English: -You should stop taking OSSEOR if you have to take oral tetracyclines or quinolones (two types of antibiotics).
Danish: - Hvis De skal have antibiotika såsom tetracykliner og quinoloner til indtagelse gennem munden, bør De holde op med at tage OSSEOR.
English: OSSEOR is contra-indicated in patients with a past history of venous thromboembolic events (see section 4.3) and should be used with caution in patients at risk of VTE.
Danish: OSSEOR er kontraindiceret hos patienter med VTE i anamnesen (se pkt.
English: If the patient has developed SJS, TEN or DRESS with the use of OSSEOR, OSSEOR must not be restarted in this patient at any time.
Danish: DRESS ved behandling med OSSEOR, må behandling med OSSEOR ikke genoptages på et senere tidspunkt.
English: What osseor is and what it is used for
Danish: • OSSEOR skal anvendes med forsigtighed til:
English: Luxembourg/Luxemburg S.A. Servier Benelux N.V. Tel: +32 (0)2 529 43 11
Danish: Luxembourg/Luxemburg S.A. Servier Benelux N.V.
English: Hepatic impairment
Danish: Hepatitis
English: 6.3 Shelf life - 3 years.
Danish: 4.3 og 4.4).
English: Patients with hepatic impairment
Danish: Procentdel patienter, der får bivirkningen Behandling
English: Skin reactions
Danish: Knoglemarvssvigt
English: Moreover, the intended uses do not require medical supervision.
Danish: Desuden kræver de påtænkte anvendelser ikke lægeligt tilsyn.
English: This means that, although there is insufficient evidence from clinical trials, the effectiveness of these herbal medicines is plausible and there is evidence that they have been used safely in these ways for at least 30 years (including at least 15 years within the EU).
Danish: Dette betyder, at selv om der ikke er tilstrækkelig dokumentation fra kliniske undersøgelser, kan det antages, at disse plantelægemidler har en virkning, og der er dokumentation for for, at de har været anvendt sikkert på denne måde i mindst 30 år (herunder mindst 15 år inden for EU).
English: Melissa leaf should only be used in adults and children over the age of 12 years.
Danish: Citronmelisse bør kun anvendes til voksne og børn over 12 år.
English: This may be used to prepare extracts or tinctures (an alcoholic extract of the plant material).
Danish: Dette kan benyttes til at fremstille ekstrakter eller tinkturer (en alkoholisk ekstrakt af plantematerialet).
English: Although a possible improvement in symptoms was observed, shortcomings in the design of the study prevented any firm conclusions being drawn.
Danish: Selv om en mulig forbedring af disse symptomer blev observeret, kunne der ikke drages endelige konklusioner på grund af mangler i undersøgelsens udformning.
English: EMA/HMPC/310761/2013
Danish: Citronmelisse EMA/HMPC/310761/2013
English: It can also be used to treat the symptoms of mild digestive disorders including bloating and flatulence (wind).
Danish: Det kan også anvendes til at behandle symptomer på milde fordøjelsesforstyrrelser, herunder oppustethed og tarmluft (flatulens).
English: Melissa leaf is the common name for the leaf of the plant Melissa officinalis L. The plant is cultivated or gathered to obtain the leaf for medicinal use.
Danish: Citronmelisse er fællesnavnet for blade fra planten Melissa officinalis L. Planten dyrkes eller indsamles for at høste bladene til medicinsk anvendelse.
English: In its assessment, the HMPC took into account the well documented use of Melissa leaf for these indications.
Danish: HMPC har i sin vurdering taget hensyn til den veldokumenterede anvendelse af citronmelisse til disse indikationer.
English: The HMPC conclusions on the use of melissa leaf medicines for mild symptoms of stress, sleep aid and mild digestive disorders are based on their ‘traditional use' in these conditions.
Danish: HMPC's konklusioner om anvendelsen af lægemidler med citronmelisse til milde stresssymptomer, søvnhjælp og milde fordøjelsesforstyrrelser, er baseret på deres "traditionelle anvendelse" til disse tilstande.
English: Melissa leaf can also be found in combination with other herbal substances in some herbal medicines.
Danish: Citronmelisse findes desuden kombineret med andre droger i visse plantelægemidler.
English: Any applications for the licensing of medicines containing melissa leaf have to be submitted to the national authorities responsible for medicinal products, which will assess the application for the herbal medicine and take into account the scientific conclusions of the HMPC.
Danish: Ansøgninger om godkendelse af lægemidler, der indeholder citronmelisse, skal indsendes til de nationale lægemiddelmyndigheder, som vurderer ansøgningen om plantelægemidlet og tager hensyn til HMPC's videnskabelige konklusioner.
English: Further information on the HMPC assessment of melissa leaf medicines, including details of the Committee's conclusions, can be found under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Danish: Yderligere oplysninger om HMPC's vurdering af lægemidler, der indeholder citronmelisse, herunder detaljerede oplysninger om udvalgets konklusioner, findes under "All documents" på Det Europæiske Lægemiddelagenturs websted: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Further information on the risks associated with melissa leaf medicines, including the appropriate precautions for their safe use, can be found in the monograph under the tab ‘All documents' on the Agency's website: ema.europa.eu/Find medicine/Herbal medicines for human use.
Danish: Yderligere oplysninger om risici forbundet med lægemidler, der indeholder citronmelisse, herunder passende forholdsregler, som skal følges med henblik på sikker anvendelse, findes i monografien under fanebladet "All documents" på Det Europæiske Lægemiddelagenturs websted: ema.europa.eu/Find medicine/Herbal medicines for human use.
English: Detailed instructions on how to take melissa leaf medicines and who can use them can be found in the package leaflet that comes with the medicine.
Danish: Detaljerede anvisninger for, hvordan lægemidler med citronmelisse skal anvendes, og hvem der kan bruge dem, findes i indlægssedlen i lægemiddelpakningen.
English: Information on the use and licensing of melissa leaf medicines in EU Member States should be obtained from the relevant national authorities.
Danish: Oplysninger om anvendelse og godkendelse i EU's medlemsstater af lægemidler, der indeholder citronmelisse, skal indhentes fra de relevante nationale myndigheder.
English: This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of melissa leaf.
Danish: Dette er et sammendrag af Udvalget for Plantelægemidlers (HMPC) videnskabelige konklusioner angående den medicinske anvendelse af citronmelisse.
English: The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing melissa leaf.
Danish: EU's medlemsstater tager hensyn til HMPC's konklusioner, når de vurderer ansøgninger om godkendelse af plantelægemidler, der indeholder citronmelisse.
English: The HMPC also considered published clinical studies, including a small study that examined the effects of melissa leaf preparations on symptoms of mild to moderate anxiety and sleep disturbance.
Danish: Publicerede kliniske undersøgelser er taget i betragtning, herunder en lille undersøgelse, hvor citronmelisses virkning på mild til moderat angst og søvnbesvær blev undersøgt.
English: This summary is not intended to provide practical advice on how to use medicines containing melissa leaf.
Danish: Dette sammendrag er ikke en praktisk vejledning i, hvordan plantelægemidler, der indeholder citronmelisse, anvendes.
English: Herbal medicines containing melissa leaf are usually available as a herbal tea to be drunk, and in solid and liquid forms to be taken by mouth.
Danish: Plantelægemidler med citronmelisse fås normalt som en urtete samt i fast og flydende form til indtagelse gennem munden.
English: How are melissa leaf medicines approved in the EU?
Danish: Hvordan godkendes lægemidler, der indeholder citronmelisse, i EU?
English: What evidence supports the use of melissa leaf medicines?
Danish: Hvilken dokumentation underbygger anvendelsen af lægemidler med citronmelisse?